Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 9, 2015, Pages 16140-16148

  Zhang, Feng ^a   Yu, You ^a   Xing, Lina ^a   Chen, Min ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cetuximab; Chemotherapy; EGFR; Lung cancer; Salvage therapy

Indexed keywords

CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PEMETREXED;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84946606676     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Kosmidis P. Chemotherapy in NSCLC: historical review. Lung Cancer 2002; 38 Suppl 3: S19-22.
2. De Geer A, Eriksson J and Finnern HW. A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies. J Med Econ 2013; 16: 134-149.
3. Tsim S, O'Dowd CA, Milroy R and Davidson S. Staging of non-small cell lung cancer (NSCLC): a review. Respir Med 2010; 104: 1767-1774.
4. Gelsomino F, Agustoni F, Niger M, Valota M and Haspinger ER. Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story. J Clin Oncol 2013; 31: 3291-3293.
5. Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, Peters GJ, Petronini PG and Ardizzoni A. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Curr Pharm Des 2013; 19: 818-832.
6. Gao G, Ren S, Li A, Xu J, Xu Q, Su C, Guo J, Deng Q and Zhou C. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int J Cancer 2012; 131: E822-829.
7. Schmid-Bindert G, Gebbia V, Mayer F, Arriola E, Marquez-Medina D, Syrigos K, Biesma B, Leschinger MI, Frimodt-Moller B, Ripoche V, Myrand SP, Nguyen TS, Hozak RR, Zimmermann A, Visseren-Grul C and Schuette W. Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer 2013; 81: 428-434.
8. Charpidou A, Blatza D, Anagnostou V and Syrigos KN. Review. EGFR mutations in non-small cell lung cancer--clinical implications. In Vivo 2008; 22: 529-536.
9. Saif MW. Colorectal cancer in review: the role of the EGFR pathway. Expert Opin Investig Drugs 2010; 19: 357-369.
10. Rabinowits G and Haddad RI. Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 2012; 48: 1085-1089.
11. Zahorowska B, Crowe PJ and Yang JL. Com-bined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol 2009; 135: 1137-1148.
12. Yewale C, Baradia D, Vhora I, Patil S and Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 2013; 34: 8690-8707.
13. Govindan R. A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 2010; 11: 8-12.
14. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004; 59: 21-26.
15. Arnold D, Peinert S, Voigt W and Schmoll HJ. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist 2006; 11: 602-611.
16. Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 2012; 83: 407-421.
17. Garassino MC, Borgonovo K, Rossi A, Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati P, Bianchi C, Farina G and Torri V. Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res 2009; 29: 2691-2701.
18. Glover KY, Perez-Soler R and Papadimitrado-poulou VA. A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer. Semin Oncol 2004; 31: 83-92.
19. Remon J, Moran T, Majem M, Reguart N, Dalmau E, Marquez-Medina D and Lianes P. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins. Cancer Treat Rev 2014; 40: 93-101.
20. Hammerman PS, Janne PA and Johnson BE. Resistance to Epidermal Growth Factor Re-ceptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 2009; 15: 7502-7509.
21. Wozniak AJ. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors. J Thorac Oncol 2009; 4: S1084-1085.
22. Hoyle M, Crathorne L, Peters J, Jones-Hughes T, Cooper C, Napier M, Tappenden P and Hyde C. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Health Technol Assess 2013; 17: 1-237.
23. Lin H, Jiang J, Liang X, Zhou X and Huang R. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010; 70: 57-62.
24. Blick SK and Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007; 67: 2585-2607.
25. Gatzemeier U, von Pawel J, Vynnychenko I, Zatloukal P, de Marinis F, Eberhardt WE, Paz-Ares L, Schumacher KM, Goddemeier T, O'Byrne KJ and Pirker R. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011; 12: 30-37.
26. Detterbeck FC, Boffa DJ and Tanoue LT. The new lung cancer staging system. Chest 2009; 136: 260-271.
27. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
29. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. J Am Statis Assoc 1958; 53: 457-481.
30. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995; 13: 1221-1230.
31. Cho BC, Im CK, Park MS, Kim SK, Chang J, Park JP, Choi HJ, Kim YJ, Shin SJ, Sohn JH, Kim H and Kim JH. Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 2007; 25: 2528-2533.
32. Watanabe S, Tanaka J, Ota T, Kondo R, Tanaka H, Kagamu H, Ichikawa K, Koshio J, Baba J, Miyabayashi T, Narita I and Yoshizawa H. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer 2011; 11: 1.
33. Wong MK, Lo AI, Lam B, Lam WK, Ip MS and Ho JC. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 2010; 65: 1023-1028.
34. Saito H, Murakami S, Kondo T, Oshita F, Noda K and Yamada K. Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months. Onkologie 2012; 35: 18-22.
35. Kaira K and Yamamoto N. Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer. Onkologie 2012; 35: 8-9.
36. Maruyama R, Wataya H, Seto T and Ichinose Y. Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer. Anticancer Res 2009; 29: 4217-4221.
37. Kaira K, Naito T, Takahashi T, Ayabe E, Shimoyama R, Kaira R, Ono A, Igawa S, Shukuya T, Murakami H, Tsuya A, Nakamura Y, Endo M and Yamamoto N. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 2010; 68: 99-104.
38. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, Sun Y, Liao ML, Osterlind K, Reck M, Armour AA, Shepherd FA, Lippman SM and Douillard JY. Gefitinib versus docetaxel in pre-viously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lan-cet 2008; 372: 1809-1818.
39. Wu JY, Shih JY, Chen KY, Yang CH, Yu CJ and Yang PC. Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations. Medicine (Baltimore) 2011; 90: 159-167.
40. Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ and Park K. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer 2010; 69: 323-329.
41. Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA and Riely GJ. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 2011; 17: 2521-2527.
42. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.